Tysabri (natalizumab; Biogen) is an intravenous humanized monoclonal antibody indicated for the treatment of moderately to severely active Crohn’s disease. It inhibits alpha-integrin cell adhesion proteins, preventing the migration of lymphocytes into the gut and subsequent inflammation.
LIST OF FIGURES
9 Figure 5: Patient-based forecast methodology for COPD
10 Figure 10: Anoro for COPD – SWOT analysis
13 Figure 38: Stiolto Respimat for COPD – SWOT analysis
20 Figure 7: Datamonitor Healthcare’s drug assessment summary of Advair for COPD
21 Figure 12: Arcapta for COPD – SWOT analysis
5 Figure 9: Datamonitor Healthcare’s drug assessment summary of Advair for COPD
LIST OF TABLES
7 Table 2: Tysabri pivotal trial data in Crohn’s disease
14 Table 3: Tysabri sales for Crohn’s disease in the US ($m), 2016–25
17 Table 4: Tysabri drug profile
18 Table 5: Tysabri pivotal trial data in multiple sclerosis
25 Table 6: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.